NCT01122511 - Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Subfoveal Choroidal NeovascularizationAge-Related Maculopathy

Interventions

DRUG

700 ug dexamethasone

Intravitreal injection of 700 ug dexamethasone into study eye

BIOLOGICAL

ranibizumab

Intravitreal injection of ranibizumab into study eye

OTHER

sham

Sham needle-less injection administered in the study eye

Trial Locations (2)

Fort Myers

Abilene